Search

Introduction: A growing number of studies have explored the association between the pretreatment lymphocyte-to-monocyte ratio (LMR) and survival outcomes in various cancers. However, its prognostic significance on bladder cancer remains inconsistent. The aim of this meta-analysis was to evaluate the prognostic value of pretreatment LMR in bladder cancer., Methods: The MEDLINE, EMBASE, Cochrane Library, and CNKI databases were comprehensively searched for relevant studies. A meta-analysis of overall survival (OS), recurrence-free survival (RFS), or cancer-specific survival (CSS) clinicopathological features was conducted., Results: Nine studies containing 5,638 cancer patients were analyzed in this meta-analysis. Patients with high LMR tended to have favourable OS (HR: 0.63, 95% CI: 0.50-0.80, P < 0.001), RFS (HR: 0.59, 95% CI: 0.38-0.91, P = 0.017), and CSS (HR: 0.76, 95% CI: 0.70-0.83, P < 0.001). Moreover, low LMR was highly correlated with age (≥60), differentiation (low), T stage (III-IV), lymph node metastasis (yes), and concomitant Cis (yes)., Conclusion: Pretreatment LMR might be a useful predictor of survival outcomes in patients with bladder cancer.

Introduction: Recently, the prognostic value of the lymphocyte-to-monocyte ratio (LMR) has been widely evaluated in multiple malignancies. However, its prognostic value in patients with esophageal squamous cell carcinoma (ESCC) remains controversial. Herein, we perform a meta-analysis to assess the prognostic value of the preoperative LMR in ESCC., Methods: Relevant studies were systematically retrieved from the online Cochrane, MEDLINE, and EMBASE databases published until March 2018. Data from studies reporting a hazard ratio (HR) and 95% confidence interval (CI) were weighted by generic inverse-variance and pooled in either fixed-effects models or random effects meta-analysis. Seven eligible studies involving 1701 patients were analyzed in this meta-analysis., Results: The synthesized analysis showed that patients with low LMR had a significantly shorter overall survival (OS) (HR: 0.67, 95% CI: 0.58-0.78, p < 0.001) and disease-free survival (DFS)/progression-free survival (PFS) (HR: 0.67, 95% CI: 0.50-0.92, p = 0.01). Additionally, low LMR was correlated with TNM stage (III-IV vs. I-II; HR = 1.94, 95% CI: 1.16-3.22, P = 0.01) and tumor recurrence (yes vs. no; HR = 1.71, 95% CI: 1.06-2.77, P = 0.03)., Conclusion: Low LMR was associated with advanced clinicopathological features and poor prognosis as a predicative biomarker in patients with ESCC., (Copyright © 2018 Elsevier B.V. All rights reserved.)

Aim: To assess the prognostic value of the preoperative lymphocyte-to-monocyte ratio (LMR) in patients with breast cancer (BC)., Methods: Relevant studies were systematically retrieved from the online Cochrane, MEDLINE, EMBASE and CNKI databases published until February 2018. The end points were overall survival (OS), disease-free survival (DFS), and clinicopathological parameters. Meta-analysis was performed using hazard ratios (HRs) or odds ratios (ORs) and their 95% confidence intervals (CIs) as effect measures., Results: Ten studies with 5667 individuals were included. The synthesized analysis demonstrated that that low LMR was significantly associated with poor OS (HR: 0.65, 95% CI: 0.47-0.90, p = .009) and DFS (HR: 0.60, 95% CI: 0.49-0.74, p < .001). Subgroup analyses revealed that the negative prognostic impact of low LMR on OS outcomes remained substantial in Asian populations, triple-negative patients, and patients with non-metastatic and mixed stage. However, low LMR was not significantly related to clinicopathological features., Conclusion: The preoperative LMR might be a predictive factor of poor prognosis for BC patients., (Copyright © 2018 Elsevier B.V. All rights reserved.)

Background: An increasing number of studies have investigated the prognostic value of the lymphocyte-to-monocyte ratio (LMR) in various types of cancer. The present meta-analysis was designed to investigate its prognostic value of pretreatment LMR in pancreatic cancer (PC)., Methods: An integrated meta-analysis was conducted and eligible studies were recruited by a systematic search in MEDLINE, EMBASE, and Cochrane databases. The association between LMR and survival outcomes and clinicopathological features were analyzed in PC patients., Results: A total of 10 studies (11 cohorts) comprising 2557 patients were included in this meta-analysis. The result demonstrated that low LMR could predict unfavorable overall survival(OS) (HR: 0.60, 95% confidence interval [CI]: 0.50-0.71, p < 0.001) and disease-free survival (DFS)/recurrence-free survival (RFS) (HR: 0.43, 95% CI: 0.20-0.94, p = 0.03). Moreover, low LMR was also positively correlated with male patients, CA199, and TNM stage., Conclusions: This study suggested that low pretreatment LMR was associated with advanced clinicopathological features and poor prognosis as a predicative factor in patients with PC., (Copyright © 2018 Elsevier B.V. All rights reserved.)

Background: Recently, the lymphocyte-to-monocyte ratio (LMR) has been reported to be a prognostic factor in multiple malignancies. The current study was designed to assess the prognostic value of pretreatment LMR in gastric cancer (GC)., Methods: MEDLINE, EMBASE, Cochrane, and CNKI databases were searched until April 2017. Eligible articles were defined as studies assessing the prognostic role of pretreatment LMR in GC. Pooled hazard ratios (HRs) for overall survival (OS), disease-free survival (DFS), and recurrence-free survival (RFS) were calculated using fixed-effects or random-effects models., Results: A total of six studies comprising 4908 patients were included in the study. Pooled results showed that low LMR was significantly associated with decreased OS (HR: 0.66, 95% confidence interval [CI]: 0.54-0.82, p < .001), but not with poor DFS/RFS (HR: 0.71, 95% CI: 0.38-1.32, p = .004). The unfavorable prognostic impact of low LMR on OS was observed in patients of different disease stages and cut-off values. Moreover, low LMR was significantly related to age (>median), gender (male), CEA (>5 ng/ml), tumor size (>3 cm), TNM stage (III-IV), lymph node metastasis, and distant metastasis., Conclusions: Low pretreatment LMR may be a significant prognostic biomarker for poor OS in patients with GC., (Copyright © 2018 IJS Publishing Group Ltd. Published by Elsevier Ltd. All rights reserved.)